A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 Results of Post hoc analysis of pooled data from NCT01786668 and NCT03502616 trials presented at the ACR Convergence 2023.
03 Jun 2023 Results of pooled hoc analysis (n=269) assessing the median time to improvement of pain, morning stiffness and disease activity in tofacitinib-treated pts with AS presented at the 24th Annual Congress of the European League Against Rheumatism
03 Jun 2023 Results of pooled post hoc analysis (n=372 from studies NCT01786668 and NCT03502616) assessing the impact of BL CRP levels on tofacitinib efficacy and safety in pts with AS presented at the 24th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com